Despite the regulatory setback, BioArctic's partner Eisai has stated that the safety profile of lecanemab reported in clinical practice in the United States, Japan, and other countries is consistent ...

The European Commission said on Friday that it has launched infringement procedures against Bulgaria for failing to fully ...

The European Commission (EC) has presented data regarding several criminal proceedings linked to the enforcement of EU law, with Bulgaria involved in seven of these cases. In the realm of crime ...

AstraZeneca (AZN) stock in focus as its partner Daiichi Sankyo (DSNKY) wins EU backing for their jointly developed breast ...

Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, “Eisai”) and (Nasdaq: BIIB, Corporate headquarters: Cambridge, ...

Unife has warned that EU member states are at risk of losing funding for vital rail schemes promised in the EU's Recovery and ...

Merck (MRK) announced that the Committee for Medicinal Products for Human Use, or CHMP, of the European Medicines Agency, or EMA, recommended ...

The European Commission has requested its medicines regulator to consider safety information on Eisai and Biogen's ...

Biogen (BIIB) stock in focus as company and partner Eisai (ESALF) face delay in the EU launch of Alzheimer's drug lecanemab.

Biogen (BIIB) and Eisai announced an update on the ongoing regulatory review of the Marketing Authorization Application for lecanemab as ...

The Ukrainian media, suddenly left without money, started a campaign to find fakes in the Russian media. So my cat, after ...

Amgen’s Blincyto (blinatumomab) has been approved by the European Commission (EC) to treat certain acute lymphoblastic ...